Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Chen, L.-T.; Wang‐Gillam, Andrea; Li, C.-P.; Bodoky, G.; Dean, Andrew; Shan, Yan–Shen; Jameson, Gayle; Macarulla, Teresa; Lee, K.-H.; Cunningham, David; Blanc, Jean Frédéric; Chiu, Chang Fang; Schwartsmann, Gilberto; Braiteh, Fadi; Belanger, Bruce; Bayever, E.; Jong, F. de; Hoff, Daniel D. Von; Siveke, Jens T.

doi:10.1093/annonc/mdw371.14

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although irinotecan is a very potent anticancer drug, its application in free form is hampered by severe side effects that lead to poor patient compliance. While liposomal irinotecan alone did not improve overall survival as compared to 5-FU/LV in pancreatic cancer patients, the combination of liposomal irinotecan and 5-FU/LV significantly improved overall survival with very acceptable toxicity profiles 66,67 . A similarly promising systemic combination therapy is nanoparticle albumin-bound paclitaxel (Abraxane®) combined with the immune checkpoint inhibitor atezolizumab, which together induced unprecedented therapeutic responses in triple-negative breast cancer patients 68 .…”

Section: Systemic Combination Therapiesmentioning

confidence: 88%

Smart cancer nanomedicine

et al. 2019

View full text Add to dashboard Cite

Nanomedicines are extensively employed in cancer therapy. We here propose four strategic directions to improve nanomedicine performance and translation. (1) Patient stratification has become common practice in oncology drug development. Accordingly, probes and protocols for patient stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclusion in clinical trials. (2) Rational drug selection is crucial for clinical and commercial success. Opportunistic choices based on drug availability should be replaced by investments in modular (pro)drug and nanocarrier design. (3) Combination therapies are the mainstay of clinical cancer care. Nanomedicines synergize with pharmacological and physical co-treatments, and should be increasingly integrated in multimodal combination therapy regimens. (4) Immunotherapy is revolutionising the treatment of cancer. Nanomedicines can regulate the behaviour of myeloid and lymphoid cells, thereby empowering anticancer immunity and immunotherapy efficacy. Alone and especially together, these four directions will fuel and foster the development of successful cancer nanomedicine therapies.

show abstract

Section: Systemic Combination Therapiesmentioning

confidence: 88%

Smart cancer nanomedicine

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Another new treatment option for metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy is the combination of nanoliposomal irinotecan (nal-IRI) with 5-FU/LV. The NAPOLI-1 trial showed that, after 313 events, nal-IRI + 5-FU/ LV significantly improved median overall survival compared to 5-FU/LV alone (6.1 vs. 4.2 months) [3]. However, there is still an imperative need for alternative treatment options to achieve more effective and durable clinical responses.…”

mentioning

confidence: 99%

Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends

Cheung¹,

Lutz²,

Siveke³

2018

Oncol Res Treat

View full text Add to dashboard Cite

Pancreatic cancer is among the most aggressive malignancies with no effective therapeutic options thus far. Immunotherapy has recently emerged as a promising alternative for the treatment of various solid tumors. In particular, promising results in clinical trials were observed for therapies targeting immune checkpoint molecules. Efforts have been put into investigating the potential of immunotherapy in treating pancreatic cancer. While most of the clinical trial results are still being awaited, several intrinsic features of pancreatic cancer such as low mutational load and the presence of highly immunosuppressive desmoplasia significantly hamper the efficacy of immunotherapy in this disease. These unique features of pancreatic cancer, however, have advanced our understanding of tumor immunology and might help to tailor the future direction of immunotherapy. In this review, we summarize the current immunotherapeutic strategies and clinical trials targeting checkpoint molecules in pancreatic cancer. Emerging trends towards various combinations with therapies targeting immunosuppressive myeloid cells are also discussed.

show abstract

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma

Lamb

Scott

2017

Drugs

View full text Add to dashboard Cite

Intravenous liposomal irinotecan injection (Onivyde) is approved for use in combination with 5-fluorouracil and leucovorin (5-FU/LV) in patients with metastatic pancreatic adenocarcinoma that has progressed following gemcitabine-based therapy. Liposomal irinotecan is a liposome-encapsulated formulation of the topoisomerase-1 inhibitor irinotecan, developed to overcome the pharmacological and clinical limitations of non-liposomal irinotecan. In the pivotal multinational, phase III NAPOLI-1 trial in patients with metastatic pancreatic adenocarcinoma that had progressed following gemcitabine-based therapy, liposomal irinotecan in combination with 5-FU/LV significantly prolonged median overall survival (OS; primary endpoint) and median progression-free survival (PFS) at the time of the primary analysis (after 313 events) and final analysis (after 382 events) compared with 5-FU/LV control therapy. The objective response rate was also significantly higher in the liposomal irinotecan plus 5-FU/LV group than in the control group. Liposomal irinotecan-based combination therapy had a manageable safety profile; the most common treatment-emergent adverse events (TEAEs) of grade ≥3 severity were haematological or gastrointestinal in nature. The incidence of neutropenic sepsis was low. In a setting where there is a paucity of second-line treatment options, liposomal irinotecan in combination with 5-FU/LV is an important emerging treatment option for metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy.

show abstract

Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Cited by 4 publications

References 0 publications

Smart cancer nanomedicine

Smart cancer nanomedicine

Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma

Contact Info

Product

Resources

About